| Identification | Back Directory | [Name]
GSK-340 | [CAS]
2222509-79-5 | [Synonyms]
GSK-340
Ethanone, 1-[(2S)-2-cyclopropyl-3,4-dihydro-4-[[2-(hydroxymethyl)phenyl]methyl]-6-(1,2,3,6-tetrahydro-4-pyridinyl)-1(2H)-quinoxalinyl]- | [Molecular Formula]
C26H31N3O2 | [MOL File]
2222509-79-5.mol | [Molecular Weight]
417.54 |
| Hazard Information | Back Directory | [Uses]
GSK-340 is a BET inhibitor with high affinity and significant selectivity for BD2 from BRD4 with a pIC50 of 7.2. GSK-340 inhibits MCP-1 release in Lipopolysaccharide (HY-D1056) treated PBMCs and whole blood with the pIC50 of 7.4 and 6.0, respectively. GSK-340 has immunomodulatory activity[1]. | [References]
[1] Law RP, et al. Discovery of Tetrahydroquinoxalines as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the Second Bromodomain. J Med Chem. 2018 May 24;61(10):4317-4334. DOI:10.1021/acs.jmedchem.7b01666 |
|
|